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Abstract: Cannabinoids are the constituents of the marijuana plant (Cannabis sativa). There are numerous cannabinoids 
and other natural compounds that have been reported in the cannabis plant. The recent progress in marijuana-cannabinoid 
research include the discovery of an endocannabinoid system with specific genes coding for cannabinoid receptors 
(CBRs) that are activated by smoking marijuana, and that the human body and brain makes its own marijuana-like 
substances called endocannabinoids that also activate CBRs. This new knowledge and progress about cannabinoids and 
endocannabinoids indicate that a balanced level of endocannabinoids is important for pregnancy and that the breast milk 
in animals and humans has endocannabinoids for the growth and development of the new born. There are two well 
characterized cannabinoid receptors termed CB1-Rs and CB2-Rs and these CBRs are perhaps the most abundant G-
protein coupled receptors that are expressed at high levels in many regions of the mammalian brain. The expression of 
CB1-Rs in the brain and periphery and the identification of CB2-Rs in immune cells and during inflammation has been 
extensively studied and characterized. However, the expression of functional neuronal CB2-Rs in the CNS has been much 
less well established and characterized in comparison to the expression of abundant brain CB1-Rs and functional neuronal 
CB2-Rs has ignited debate and controversy. While the issue of the specificity of CB2-R antibodies remains, many recent 
studies have reported the discovery and functional characterization of functional neuronal CB2-Rs in the CNS beyond 
neuro-immuno cannabinoid activity. 
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FUNCTIONAL NEURONAL CB2 CANNABINOID 
RECEPTORS IN THE CNS 
  Cannabinoids are the constituents in marijuana and endo-
cannabinoids (eCBs) are the endogenous marijuana-like sub-
stances found in animals and humans [1]. Recent advances in 
cannabinoid research indicate the existence of an endocan-
nabinoid system (ECS) consisting of genes encoding can-
nabinoid receptors (CB1-Rs and CB2-Rs), their endogenous 
ligands eCBs and proteins that synthesize and degrade these 
eCBs. Both CB1-Rs and CB2-Rs are distributed in the brain 
and peripheral tissues and are activated by endocannabi-
noids, and cannabinoids, the active constituents in marijuana 
[1]. For many years it was thought that marijuana use, phy-
tocannabinoids and eCBs act by activating brain-type can-
nabinoid receptors (CBRs) called CB1-Rs, and that a second 
type called CB2-Rs were found in peripheral tissues and 
mainly in immune cells and were referred to as peripheral 
CB2-Rs. This was because many investigators were not able 
to detect the presence of neuronal CB2-Rs in healthy brains 
[2-4], but CB2-R expression were demonstrated in rat mi-
croglia cells and other brain-associated immune cells during 
inflammation [5-10]. Despite the evidence that CB2-Rs 
might be present in the CNS, the expression of neuronal 
CB2-Rs in the CNS has been much less well established and 
characterized in comparison to the expression of abundant  
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brain CB1-Rs. We and others and many recent studies have 
reported the discovery and functional characterization of 
neuronal brain CB2-Rs. A number of studies from mice to 
human subjects, using a variety of techniques including those 
used in pain models, histological, immunohistochemical, in 
situ hybridization, electron microscopy, molecular biologi-
cal, behavioral and pharmacological, pharmacological MRI, 
cerebral occlusion and hemicerebellectomy, transgenic and 
cell culture studies show the functional presence of CB2-Rs 
in neural progenitor cells, neurons, glial and endothelial cells 
[11-14]. 
  These functional neuronal CB2-Rs have ignited debate 
and controversy, and its possible involvement in drug addic-
tion and neuropsychiatric disorders is intensely under re-
evaluation. While the role of CB2-Rs in CNS disturbances 
involving neuroinflammation and neuropathic pain have 
been extensively reported [15], our studies provided the first 
evidence for a role of CB2-Rs in depression, schizophrenia 
and in the effects of substance abuse [15, 16 and 17]. The 
controversy of the functional expression of brain neuronal 
CB2-Rs remain because CNR2 gene and CB2-Rs have re-
ceived much less attention than CB1-Rs. Although the ex-
pression of CB1-Rs in the brain and periphery has been well 
studied, many features of CNR2 gene structure, regulation 
and variation remain poorly characterized in comparison to 
the CNR1 gene encoding the CB1-Rs. This poor characteri-
zation of CNR2 gene structure and variants hampers progress 
in the determination of the functional role of CB2-Rs in a 
number of CNS disturbances. Additionally, the CNS pres-
ence of CB2-Rs may no longer be a debate, but the neurobi-206    Current Neuropharmacology, 2011, Vol. 9, No. 1  E.S. Onaivi 
ological basis for CB2-R physiological activity and its inter-
action with or without CB1-Rs remains to be determined. 
Therefore, an overwhelming number of studies now docu-
ment CB2-R expression in neuronal, endothelial and glial 
cells. Mounting evidence also shows that CB2-Rs and its 
gene variants may play possible roles in neuroinflammation 
occurring in multiple sclerosis, traumatic brain injury,   
HIV-induced encephalitis, Alzheimer’s, Parkinson’s and 
Huntington’s diseases [18 and 19]. A central neuronal but 
glial independent neuroprotection by CB2-R activation was 
reported to counteract apoptotic cell death that is induced by 
remote axonal damage that is achieved through PI3K/Akt 
signaling [14]. Functional interactions between forebrain 
CB2-R and mu-opioid receptor (MOR) was demonstrated 
[20] and CB2-R antagonist SR144528 was reported to de-
crease MOR expression and activation in mouse brainstem 
[21]. Upon our discovery of the presence and functional ex-
pression of cannabinoid CB2-Rs in the brain [22], most re-
cent studies have confirmed that CB2-Rs are present in both 
cultured neural cells and the nervous system of several 
mammals such as rodents, monkeys and humans under nor-
mal conditions [23]. Thus CB2-Rs have been implicated in 
the control of fundamental neural cell processes, such as 
proliferation and survival. It was therefore suggested that 
manipulating CB2-Rs might be useful for delaying the pro-
gression of neurodegenerative disorders and inhibiting the 
growth of glial tumors [23]. CB2-Rs have also been shown 
sub-serving differential physiological roles in other neuro-
anatomical sites such as the brain stem, cortex, cerebellum, 
PAG, substantia nigra, hippocampus, thalamus, pineal gland 
and pinealocytes [7, 8, 24-27]. CB2-Rs in the pineal gland 
along with other components of the ECS may be involved in 
the control of pineal physiology [28]. Gender-dependent 
changes on the expression of hippocampal CB1 and CB2-Rs 
were demonstrated in the early maternal deprivation model 
in neonatal rats [27]. While CB1-Rs remain one of the most 
ubiquitous G-protein coupled receptors in the mammalian 
brain, we have described the multifocal distribution of CB2-
Rs albeit at lower levels than the CB1-Rs in neuronal and 
glial processes in a number of brain areas [25]. This multifo-
cal distribution and the presence of CNS brain CB2-Rs sug-
gest a need to re-evaluate the role of these receptors in neu-
rotransmission. It is important to understand the role of CB2-
Rs and its gene variants in the CNS and its possible in-
volvement drug addiction and neuropsychiatric disorders. 
Research however on the involvement of CB2-Rs in neuroin-
flammatory conditions and in neuropathic pain has advanced 
more than other areas in neuropsychiatry and drug addiction. 
Therefore, improved information about CNR2 gene and its 
human variants might add to our understanding, not only of 
the role of CB2-Rs during neuroinflammatory conditions in 
the CNS but also beyond neuro-immuno-cannabinoid activ-
ity. 
  Many previous studies could not detect the expression of 
CB2-Rs in the brain [2, 4 and 29], because the PCR primers 
may not have been specific to detect CB2-R isoforms. Fur-
thermore, the specificity of the available antibodies for both 
CB1 and CB2-Rs has also been controversial as some could 
not detect the native and in some cases the transfected 
cannbinoid CBR antigen, although they recognized proteins 
in Western blot and in immunohistochemical analysis, [33]. 
There are also problems with the antibodies because of the 
species differences between human and rodent CB2 gene. 
We have resolved some of these issues by using CB2 iso-
form specific TaqMan probes that could differentiate the 
isoform-specific expression and are more sensitive and spe-
cific than CB2 antibodies that are currently available [32]. 
The controversial CB2-R brain expression could also be due 
to the low expression levels of CB2A isoform in brain re-
gions and the less specific CB2 commercial antibodies in 
immunohistochemical studies, especially those studies using 
antibodies against human hCB2 epitopes for rodent brain 
immunostaining. There are also problems with the use of the 
CB2 knockout (ko) [34] mice in Western blots and in behav-
ioral analysis. When we analyzed the CB2 knockout mice 
using the three TaqMan probes against two promoters of 
mouse CB2 gene and the deleted part of CB2 gene, we found 
that the promoters of CB2-R ko mice were still active and 
that a CB2 truncated version was expressed, indicating that 
the CB2 ko mice with ablation of the C-terminal peptides of 
131 amino acids [34] was an incomplete CB2-R knockout 
[32]. Another mouse CB2-R ko mice that has now been gen-
erated with ablation of N-terminal peptide 156 amino acid 
(Deltagen, Inc. San Mateo, CA) may clarify the specificity of 
the antibodies that were used against the N-terminal epi-
topes. Thus, contrary to prior reports that CB2-Rs were not 
expressed in the brain, we and others have now reported the 
wide distribution of CB2-Rs in brain regions, suggesting a 
re-evaluation of the role of CB2-Rs in the CNS. 
  The complete gene structure, 5’- and 3’ –UTR, and tran-
scription initiation sites of human CB2-Rs have not been 
fully characterized [22, 31], until now. After we and others 
identified and reported mouse CB2-R expression in brain 
regions [24 and 25], the specific expression of human or 
mouse CB2-R isoforms in brain regions was not known. But 
the published evidence showed significant species differ-
ences of CB2-Rs in human, mouse and rat in terms of pep-
tides, mRNA sizes, gene structure and pharmacology [2, 29 
and 30]. Therefore, the discrepancies on the CB2-R mRNA 
sizes in the literature indicated incomplete gene structure of 
CB2 gene in different species or polymorphism in the same 
species. We have discovered a novel human CNR2 gene 
promoter encoding testis (CB2A) isoform starting exon lo-
cated ca 45 kb upstream from previously identified promoter 
encoding the spleen isoform (CB2B) [32]. The size of the 
newly identified hCB2A isoform is about twice as large as 
the previously identified human hCB2B gene. The 5’ exons 
of both CB2-R isoforms are untranslated 5’UTRs and alter-
natively spliced to the major protein coding exon of CNR2 
gene. We found that CB2A is expressed higher in testis and 
brain than CB2B that is expressed higher in other peripheral 
tissues than CB2A. Using precise probes and species com-
parison, we found that the CNR2 gene of human, rat and 
mouse genomes deviated in their gene structures and isoform 
expression patterns and could be regulated by cannabinoid 
ligand treatment in the mouse model [32]. The human CB2 
gene is almost four times larger than the mouse and rat CB2 
genes [32]. If the transcription rates are similar between hu-
man and rodents, hCB2A isoform would take much longer 
time to be transcribed in the testis and brain. This will be 
unusual because other gene orthologs between humans and 
mice are usually within one fold difference in genomic sizes. CNS Neuronal CB2 Cannabinoid Receptors  Current Neuropharmacology, 2011, Vol. 9, No. 1    207 
Our data shows that there are two forms of the CB2-Rs in 
human, rat and mouse with differential subtype distribution 
specificities in the brain and peripheral organ tissues [32]. 
The promoter-specific CB2-R isoform distribution may in 
part explain why CB2-Rs were previously undetectable in 
both human and rodent brains [2, 4 and 29]. Several other 
functional studies reveal roles for CB1-Rs and CB2-Rs [34-
44]. However, our studies provided the first evidence for the 
CNS effects of CB2-Rs and its possible involvement in drug 
addiction and neuropsychiatric disorders [15-17, 45 and 46]. 
We utilized behavioral and molecular methods to study and 
determine whether there was a link between depression that 
may be a factor in drug/alcohol addiction and CNS CB2-Rs. 
First we established the use of mouse chronic mild stress 
(CMS) model of depression which has been validated and a 
widely used model for screening anti-depressants. Briefly the 
mouse CMS model measures one of the core symptoms of 
depression which is anhedonia, a lack of pleasure. Then, 
mice were subjected daily for four weeks to CMS, and anhe-
donia was measured by the consumption of sucrose solution. 
Behavioral and rewarding effects of abused substances were 
determined in the CMS and control animals. The expression 
of CB2-Rs and their gene transcripts was compared in the 
brains of CMS and control animals by Western blotting and 
RT-PCR. CMS induced gender-specific aversions in the test 
of anxiety which were blocked by WIN55212-2 and a CB2-
R agonist. In other studies we demonstrated that direct CB2-
R antisense oligonucleotide microinjection into the mouse 
brain induced anxiolysis, indicating that CB2-Rs are func-
tionally present in the brain and may influence behavior [15-
17, 45 and 46]. In another recent study, using in situ hybridi-
zation and PCR and newly designed CB2-R mRNA probes 
[32], to avoid the controversial CB2-R antibodies, the exis-
tence of CB2-R transcripts was demonstrated in a variety of 
brain areas of the primate Macaca fascicularis, including the 
cerebral cortex, hippocampus and in both external and inter-
nal divisions of the globus pallidus [47].  
  The clinical and functional implication of neuronal CB2-
Rs in the brain will gradually become clearer because more 
research will certainly unravel the contribution and interac-
tion of CB1 and CB2-Rs in drug addiction, neuropsychiatry 
and neurodegenerative disorders. The new knowledge from 
our data and those of other recent studies that CB2-Rs are 
functionally present in neurons, in the brain raises many 
questions about the possible roles that CB2-Rs may play in 
the nervous system. These results therefore extend the previ-
ous evidence that CB2-Rs are playing an important role in 
immune function to other putative neuronal function by their 
apparent presence in neuronal processes. Our studies impli-
cate neuronal and glial CB2-Rs in the chronic mild stress 
model of depression, and substance abuse. The immunohis-
tochemical localization of CB2-Rs, when compared to that of 
known CB1-R distribution in the brain, may be an indication 
of other putative functional roles of CB2-Rs in the CNS. 
Therefore both CB1 and CB2 receptors seem likely to work 
both independently and/or cooperatively in differing neu-
ronal populations to regulate important physiological activi-
ties in the central nervous system. Recent events in the clinic 
have linked the use of the anti-obesity drug, acomplia, a 
CB1-R antagonist and an appetite suppressant with a higher 
risk of depression and suicide. Our data have also showed 
associations of the CNR2 gene with depression, drug abuse, 
anorexia nervosa and schizophrenia in a human population 
and also in the CMS model of depression [17, 45] suggesting 
that the CB2-Rs may be involved in the endocannabinoid 
signaling mechanisms associated with the regulation of emo-
tionality beyond immune function. More studies are there-
fore required to determine if CB2-R ligands have the risk of 
depression or suicide that has led to the withdrawal of acom-
plia, (rimonabant) from use as an appetite suppressant in the 
control of obesity in Europe. 
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